Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome

• Published in: Journal of Crohn's and colitis 2013-10, Vol.7 (9), p.717-722
• Main Authors: García-Bosch, Orlando, Gisbert, Javier P., Cañas-Ventura, Àlex, Merino, Olga, Cabriada, José L., García-Sánchez, Valle, Gutiérrez, Ana, Nos, Pilar, Peñalva, Mireia, Hinojosa, Joaquin, García-Planella, Esther, Muñoz, Fernando, Calvet, Xavier, Panés, Julián
• Format: Article
• Language: English
• Subjects: Adalimumab; Adult; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Anti-TNF; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Colectomy; Colitis, Ulcerative - drug therapy; Colitis, Ulcerative - surgery; Female; Humans; Infliximab; Male; Remission Induction; Retrospective Studies; Surgery; Time Factors; Treatment Outcome; Ulcerative colitis; Young Adult
• ISSN: 1873-9946; 1876-4479
• DOI: 10.1016/j.crohns.2012.10.004

Information on efficacy and predictors of response to adalimumab in ulcerative colitis (UC) clinical practice is limited. Assessment of response to adalimumab and its predictors in an observational cohort study. Retrospective cohort study based on data obtained from ENEIDA registry. All patients diagnosed with UC treated with adalimumab were included. Response to adalimumab was evaluated at weeks 12, 28, and 54 according to the partial Mayo score, and requirement of colectomy until end of follow-up. 48 patients with UC treated with adalimumab were included; 39 (81.3%) had previously received infliximab. Response rates at weeks 12, 28 and 54 were 70.8%, 43.2% and 35% respectively. Response to prior treatment with infliximab was the only predictive factor of response to adalimumab at week 12, which was obtained in 90% of infliximab remitters, 53.8% of responders and 33.3% of primary non-responders (p=0.01). Colectomy was required in 11 patients (22.9%), after a mean time of 205days. The only clinical independent predictor of colectomy was non-response to adalimumab at week 12: colectomy rates were 5/34 (14.7%) in responders and 6/14 (42.9%) in non-responders (p=0.035), time free of colectomy was significantly reduced in non-responders (p=0.01). Adalimumab withdrawal due to adverse events occurred in 4.2% of patients. This study shows that adalimumab is an effective treatment in patients with UC. If used as a second anti-TNF, previous achievement of remission with the first anti-TNF predicts response, and failure to achieve response at week 12 predicts colectomy.